Fresenius Medical Care AG (FRA:FMEA)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.72B -21.5% |
| Revenue (ttm) | 19.43B -0.5% |
| Net Income | 937.78M +42.9% |
| EPS | 1.67 +50.0% |
| Shares Out | n/a |
| PE Ratio | 11.72 |
| Forward PE | 9.60 |
| Dividend | 0.52 (2.67%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | n/a |
| Open | 19.60 |
| Previous Close | 18.90 |
| Day's Range | 19.60 - 19.60 |
| 52-Week Range | 17.20 - 23.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial StatementsNews
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions exp...
Investors unlikely to find positive Fresenius take from HHS plan, says JPMorgan
After HHS published a new Kidney Care National Plan, JPMorgan said bears will focus on the strong rhetoric around the large incumbent providers, Fresenius Medical (FMS) and DaVita (DVA), and…
EQS-DD: Fresenius Medical Care AG: Martin Fischer, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2023)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.10.2026 / 17:16 CET/CEST The issuer is solely responsi...
Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and eviden...
Fresenius Medical price target lowered to $24 from $25 at Truist
Truist lowered the firm’s price target on Fresenius Medical (FMS) to $24 from $25 and keeps a Hold rating on the shares as part of broader research now previewing Q3…
Fresenius Medical Care Names Shervin Korangy CEO
(RTTNews) - Fresenius Medical Care AG (FME.DE, FME) announced that Shervin J. Korangy will become Chief Executive Officer (CEO) and Chair of the Management Board, effective October 12, 2026. He will s...
Fresenius Medical Care AG (FMS) Shares Fall 7.7% -- What GF Score of 74 Tells Investors
Fresenius Medical Care AG (FMS) Shares Fall 7.7% -- What GF Score of 74 Tells Investors
Fresenius Medical Care (FMS) Names Shervin Korangy as New CEO and Chair
Fresenius Medical Care (FMS) Names Shervin Korangy as New CEO and Chair
Fresenius Medical trading resumes
11:10 EDT Fresenius Medical (FMS) trading resumes
Fresenius Medical names Shervin Korangy as next CEO
Fresenius Medical (FMS) announced that Shervin Korangy will become Chief Executive Officer and Chair of the Management Board, effective October 12. The supervisory board unanimously appointed Korangy ...
EQS-Adhoc: Fresenius Medical Care AG : Change in CEO – Shervin J. Korangy Succeeds Helen Giza
EQS-Ad-hoc: Fresenius Medical Care AG / Key word(s): Personnel decisions / Executive Board Fresenius Medical Care AG : Change in CEO – Shervin J. Korangy Succeeds Helen Giza 07-Oct-2026 / 16:54 CET/CE...
Fresenius Medical trading halted, news pending
10:37 EDT Fresenius Medical (FMS) trading halted, news pending
Fresenius Medical downgraded to Hold from Buy at Berenberg
Berenberg downgraded Fresenius Medical (FMS) to Hold from Buy with a price target of EUR 42, down from EUR 60, following a transfer of coverage. Evidence of positive U.S. kidney…
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expe...
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
Fresenius Medical price target raised to $25.80 from $25.50 at Bernstein
Bernstein analyst Susannah Ludwig raised the firm’s price target on Fresenius Medical (FMS) to $25.80 from $25.50 and keeps a Market Perform rating on the shares. The firm notes the…
Fresenius Medical price target lowered to EUR 32.30 from EUR 37.40 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Fresenius Medical (FMS) to EUR 32.30 from EUR 37.40 and keeps an Overweight rating on the shares. Published first on…
Fresenius Medical price target lowered to EUR 31 from EUR 32 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Fresenius Medical (FMS) to EUR 31 from EUR 32 and keeps an Underweight rating on the shares.
Fresenius Medical price target lowered to $25 from $26 at Truist
Truist lowered the firm’s price target on Fresenius Medical (FMS) to $25 from $26 and keeps a Hold rating on the shares.
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year out...
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
Fresenius Medical Care AG Earnings Call Transcript: Q2 2026
Operating income grew 23% year-over-year with margin expansion and strong cash flow, despite U.S. treatment volume headwinds and regulatory challenges in China. A EUR 1 billion share buyback was completed and a second program launched, while guidance for 2026 was confirmed.
Fresenius Medical Care AG Earnings release: Q2 2026
Fresenius Medical Care AG released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Fresenius Medical Care AG Slides: Q2 2026
Fresenius Medical Care AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Fresenius Medical Care AG Quarterly report: Q2 2026
Fresenius Medical Care AG has published its Q2 2026 quarterly earnings report on August 4, 2026.